鉴定了螺旋[染色体-2,4'-二]s作为强效,选择性和Gq-偏差的5-HT2C受体部分激动剂
Guangqian Jiang1, Bingjie Zhang2,3, Xiaoya Zhang1
1Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
ACS medicinal chemistry letters
|January 17, 2024
概括
研究人员开发了新的螺旋皮皮里丁化合物,以向血清素5-HT2C受体 (5-HT2C R). 化合物8表现出强有力的和选择性的Gq偏差部分激动作用,显示出药物开发的前景.
科学领域:
- 药用化学 医学化学
- 神经药理学神经药理学
- 药物发现 药物发现 药物发现
背景情况:
- 胺5-HT2C受体 (5-HT2C R) 是神经和精神疾病的关键标.
- 开发具有特定信号偏差的选择性激动剂对于治疗疗效和最小化副作用至关重要.
研究的目的:
- 设计和合成新型的螺旋胺衍生物作为选择性5-HT2C R激动剂.
- 为潜在的治疗应用识别具有Gq信号偏差的化合物.
主要方法:
- 基于化合物的一系列螺旋胺的合成.
- 使用细胞信号测试进行评估,以确定受体的选择性和有效性.
- 结构-活性关系 (SAR) 研究以优化化合物特性.
主要成果:
- 螺旋[基-2,4'-皮丁]s作为5-HT2C R激动剂的新型化学型出现.
- 化合物8是一种7-模拟物,显示出强大且有选择性的5-HT2C R部分激动性 (EC50 = 121.5 nM).
- 化合物8对5-HT2A R或5-HT2B R没有活性,没有β-arrestin招募,并且低hERG抑制.
结论:
- 新的螺旋胺系列,特别是化合物8,代表了一个有前途的Gq偏差的5-HT2C R部分激动剂.
- 这些发现支持将化合物8作为药理工具或潜在的候选药物的发展.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
880
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
880
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
978
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
978
Transducer Mechanism: G Protein–Coupled Receptors
2.0K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
261
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
261
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K


